Conference Overview - The conference is scheduled for June 12, 2025, starting at 9 AM with registration beginning at 8 AM [1][5] - The venue is located at the Beijing Zhongguancun National Independent Innovation Demonstration Zone Exhibition Center, accessible through Gate 5 [2] - Attendees are advised against driving due to limited parking availability [3] Registration Process - Early arrival is recommended, ideally before 8:30 AM, to avoid queues and ensure seating [6] - The registration process involves scanning a QR code to access the electronic ticket, which will be verified upon arrival [8] Important Reminders - Attendees should join the designated group for updates on conference materials such as photo albums and publications [1] - It is emphasized that the conference will start promptly at 9 AM, and latecomers may not be accommodated [5]

思宇年度活动回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 即将召开： 据介绍，路得瞳是博视医疗旗下 全自主5S软性接触镜制造商 ，即自研材料、自创设计、自制模具、自造设 备、自主生产。旗下多种水凝胶和硅水凝胶材料，融合高透氧性、高柔软性、高水润性和高保湿性， 打破国 外对硅水凝胶镜片材料及量产工艺技术的垄断 。 # 注册证详情 结构及组成/主要组成成分 ： 该产品为增强着色的日戴型软性亲水接触镜。由HEMA、NVP等聚合而成，添加着色剂，聚丙烯杯包装。含水 量标称值：43%。推荐更换周期为1个月。产品经湿热灭菌，货架有效期5年。 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 2025年9月4-5日，第三届全球手术机器人大会 近日， 南京博视医疗科技有限公司（简称："博视医疗"） 旗下视力保健产品业务品牌 路得瞳 宣布， 其自主 研发的 月抛彩色隐形眼镜 正式获得国家药品监督管理局（NMPA）注册认证 ， 注册证编号为国械注准 20253161016。这是路得瞳 首款 获国家药品监督管理局认证的自主研发软镜。 2020年以来，彩片注册审批周期 ...

Core Insights - The article highlights the recent financing and strategic developments of Zhonghui Pharmaceutical, including seed and angel round funding totaling nearly 50 million yuan [1][3] - Zhonghui Pharmaceutical is positioned as the first domestic company with independent intellectual property rights in hollow microneedle technology, aiming to break foreign monopolies in this field [5] Financing and Mergers - Zhonghui Pharmaceutical completed seed and angel round financing, with investments from Xincheng Investment, Aikang Chuangtan, Shaanxi Investment Growth Fund, and others [1] - The company also announced the acquisition and restructuring of Shanghai Lanwei Medical Technology Co., Ltd [3] Product and Technology Overview - The core product of Zhonghui Pharmaceutical is the hollow microneedle, which is designed for drug delivery, vaccine injection, aesthetic injection, and biosensing applications [6] - The hollow microneedles are characterized by their painlessness, minimally invasive nature, and high drug loading capacity, achieving international advanced standards [6] - The company is developing various products, including intradermal, suprachoroidal, and scalp injection hollow microneedles [6] Research and Development - Zhonghui Pharmaceutical is constructing the first automated biological tissue sample bank in Northwest China, which will support long-term preservation and scientific research of biological resources [8] - The company has launched its first gene-edited engineered stem cells with hair growth functions and is exploring applications in type 2 diabetes and ophthalmology using exosomes and gene-edited stem cells [8]

Group 1: Industry Events - The first Global Aesthetic Technology Conference is scheduled for June 12, 2025 [1] - The second Global Medical Technology Conference will take place on July 17, 2025 [1] - The third Global Surgical Robotics Conference is set for September 4-5, 2025 [1] Group 2: Cardiovascular Innovations - Two breakthrough technologies in cardiovascular treatment were highlighted at the EuroPCR 2025: Elixir Medical's DynamX Coronary Bioadaptor and Cardiawave's Valvosoft ultrasound system [2] - DynamX Coronary Bioadaptor is designed to treat coronary artery disease (CAD) and features a unique bioabsorbable polymer coating that is fully absorbed within six months, allowing for natural vessel restoration [5][8] - Valvosoft is a non-invasive ultrasound treatment system aimed at severe symptomatic aortic stenosis, utilizing high-intensity focused ultrasound (HIFU) to soften calcified tissue without invasive surgery [16][31] Group 3: DynamX Coronary Bioadaptor - The device consists of three cobalt-chromium spiral metal stents and is the first dynamic coronary implantation technology [5] - It has shown a target lesion failure (TLF) rate of 1.9% compared to 5.5% for traditional drug-eluting stents (DES), indicating a 65% reduction in TLF [13] - The device has received CE certification and FDA breakthrough device designation, demonstrating its potential in improving coronary artery lumen diameter and reducing plaque progression [8][12] Group 4: Valvosoft Ultrasound System - Valvosoft has completed two first-in-human trials and is undergoing a pivotal study across multiple European countries to assess its safety and efficacy [19][21] - The system has shown promising results in improving hemodynamics and quality of life for patients with aortic stenosis, with significant increases in valve opening area and reductions in pressure gradients [27] - The technology is expected to pave the way for long-term treatment options for aortic stenosis and potentially other indications [25] Group 5: Company Profiles - Elixir Medical Corporation focuses on transforming cardiovascular disease treatment through innovative technologies, with a strong emphasis on drug-eluting stents and bioadaptive systems [26][28] - Cardiawave specializes in non-invasive HIFU treatment technologies, aiming to provide alternatives for patients unable to undergo traditional surgical procedures [31]

医疗科技系列年度大会回顾： 首届全球眼科大会 | 首届全球骨科大会 | 首届全球心血管大会 （注意：当天 上午为首届全球医美科技大会， 报名链接及读者福利 附文末 ； 下午有两场活动， 二、活动地点： 中关村展示中心会议中心（北京市海淀区新建宫门路2号） 三、主办单位： 思宇MedTech 、探美医界 ； 协办单位：中关村联新生物医药产业联盟 支持单位：启迪之星，中关村科学城CGT产业孵化中心 四、会议规模： 现场参会嘉宾500人 1.大型医美行业人士交流沙龙， 报名链接附文末 ； 2. 北京政府闭门对接会-仅限获奖企业参加 ，或主编一对一邀约） 一、活动时间： 2025年 6 月1 2 日 星期四 五、大会议程 如希望商务合作，联系方式如下。 报名：一场高效链接医美人的社交局 | Aesthetic LinkLab 欢迎企业积极参与思宇即将组织的大会↓ 2025年6月12日，首届全球医美科技大会 2025年7月17日，第二届全球医疗科技大会 也可以直接联系主编赵清、Alice、Jacky、Ziana 等任何思宇团队的工作人员。 【上午大会观众报名方法 读者赠票福利】 1.请先记录优惠码 SYMedTech ...

Core Insights - The article discusses the recent leadership changes at Johnson & Johnson (J&J) and GE Healthcare in China, highlighting the structural shifts in multinational companies' strategies in the region [2][17] - It emphasizes the importance of local talent in driving digital transformation and localization strategies within the medical device industry [18] Leadership Changes - J&J's Chief Digital Officer, Dai Ying, announced his departure effective June 30, 2025, after over three years in the role, with Joanna Wan temporarily taking over [1][16] - The article notes that since 2024, J&J has seen frequent changes in its Chinese executive team, including the resignation of former China President Song Weiqun, who was succeeded by Edward Zhou [1][2] - GE Healthcare is also undergoing leadership transitions, with Zhang Yihao retiring and being replaced by Song Weiqun [1][2] Dai Ying's Career Trajectory - Dai Ying spent 24 years at GE Healthcare, where he led localization strategies and digital tool implementations in China [4][6] - His roles included positions in engineering, supply chain, and innovation, culminating in his role as Vice President and Chief Innovation Officer [5][6] J&J's Q1 2025 Performance - J&J's medical technology sales reached $8.02 billion in Q1 2025, a 2.5% increase year-over-year, driven by products from Abiomed, Shockwave, and Vision [7] - The orthopedic segment reported sales of $2.241 billion, a 4.2% increase, while surgical sales were $2.396 billion, up 0.8% [10] - Cardiovascular sales reached $2.103 billion, showing a significant growth of 16.4% [13] Digital Transformation Initiatives - J&J is focusing on integrating AI-assisted diagnostic tools and remote patient management systems into its core business lines from 2023 to 2025 [12] - The Ottava™ surgical robot system is a key project, with Dai Ying playing a crucial role in its preparation for the Chinese market [14][15] Industry Observations - The article highlights the shift from a "global replication" model to a "local deconstruction" approach in multinational companies operating in China, emphasizing the need for local insights and coordination [18] - The departure of key strategic personnel can significantly impact project continuity and execution efficiency, making talent retention a critical challenge for companies like J&J [18]

Core Viewpoint - Think Surgical is accelerating its global market expansion and product development in the orthopedic surgical robot sector, particularly through the appointment of Chris Marrus as EVP to lead the TMINI surgical robot business and the 2026 growth plan [1][2]. Strategic Plan and Growth Objectives - Chris Marrus's addition signifies a pivotal step for Think Surgical in enhancing its global market reach and product innovation [2]. - The growth plan aims to increase the installation of TMINI surgical robots from 500 units to 1,500 units by the end of 2026, focusing on the U.S., Europe, and Asia-Pacific markets [2]. New Indication Development - The plan includes expanding TMINI's applications from knee replacement to hip and shoulder surgeries, with FDA approval expected in 2026 [3]. Technology Upgrades - Think Surgical is set to develop an AI-driven surgical planning algorithm, with TMINI 2.0 scheduled for launch in 2026, integrating real-time feedback during surgeries [4]. Financing Goals - The company plans to initiate a funding round of $200-300 million by the end of 2025 to support global expansion and R&D efforts [5]. About Chris Marrus - Chris Marrus brings over 20 years of experience in the medical technology industry, particularly in surgical robotics, having held significant roles at Intuitive Surgical and Mako Surgical [7]. - His previous achievements include driving over 20% annual sales growth for the da Vinci surgical system and leading the promotion of Mako Rio, which was later acquired by Stryker for $1.6 billion [7]. About THINK Surgical - Founded in 2007, THINK Surgical is based in the U.S. and specializes in developing and manufacturing robotic systems for knee replacement surgeries [10]. - The TMINI system, launched around 2022, is the world's first miniaturized surgical robot, featuring a wireless handheld device that assists surgeons with precise bone cutting during knee surgeries [10].

Core Viewpoint - The article emphasizes the collaboration between doctors, CEOs, engineers, and investors to address challenges in medical device innovation through a workshop organized by Shanghai Jiao Tong University School of Medicine and its affiliated institutions [1][4]. Training Highlights - The workshop aims to merge medical pain points with engineering technology to create innovative medical products and facilitate results transformation [4]. - Participants will learn the Biodesign innovation methodology, which is a global leading model for medical engineering innovation, focusing on efficient transformation [5]. - The program includes insights into the medical device industry trends, practical empowerment through design thinking and interdisciplinary collaboration, and opportunities for project exposure to potential investors [5]. Target Audience - The workshop is suitable for various professionals including doctors, medical technicians, engineering personnel from research institutions, industry practitioners, investors, and entrepreneurs interested in medical device innovation [5]. Course Schedule - The two-day intensive training covers medical innovation and technology layout, innovation practice, team exercises, and discussions on the key paths from concept to market [6][10][12]. - The first day includes sessions on medical innovation, technology layout, and practical exercises to foster collaboration among participants [6][8]. - The second day focuses on the industrialization of innovation and funding pathways, including a visit to the Ruijin Hospital's translational medicine center [12][15]. Expert Team - The workshop features a team of distinguished experts from Shanghai Jiao Tong University, including leaders in biomedical engineering and medical technology innovation with extensive experience in research and investment [13][16]. Registration Information - The workshop is scheduled for June 21-22, 2025, at Shanghai Jiao Tong University School of Medicine, with a fee of 8999 yuan per participant [9][18].

Core Viewpoint - The deadline for the award application for the Global MedTech Innovation Awards has been extended to June 20, 2025, to allow more time for participants to prepare and submit their materials, aiming to showcase innovations and contributions in the medical device field [1]. Group 1: Event Overview - The Global MedTech Conference 2024 will take place on July 17, 2025, at the Zhongguancun Exhibition Center in Beijing, with an expected attendance of around 500 participants from various sectors including government, hospitals, leading enterprises, startups, investment institutions, and research institutes [5]. - The conference will feature a main stage for showcasing and awarding global medical technology innovations [5]. Group 2: Award Categories - The awards to be presented include: 1. 2025 Global MedTech Innovation Award 2. 2025 Global MedTech Clinical Application Award 3. 2025 Global MedTech Service Contribution Award 4. 2025 Global MedTech Supply Chain Excellence Award 5. 2025 Global MedTech Innovation & Translation Award (Individual) [4][8]. Group 3: Application Process - The application phase is open from now until June 20, 2025, followed by a review phase from June 21 to June 29, with results to be announced between June 30 and July 4, and the awards to be presented on July 17, 2025 [12]. - Participants must fill out a specific form or send an email with required details to apply for the awards [13]. Group 4: Evaluation Criteria - The awards are aimed at various entities including medical device companies, healthcare institutions, and service providers, with criteria focusing on originality, advanced technology, clinical application, and industry impact [7][10][11]. - Specific standards are set for each award category, emphasizing the need for innovative products or technologies that demonstrate clear clinical efficacy and potential for widespread application [10][11]. Group 5: Conference Agenda - The conference will cover topics such as global medical technology development trends, research and transformation paths for imaging platforms, new consumables, brain-machine interfaces, interventional devices, diagnostic equipment, and the integration of AI in healthcare [6]. - It will also address capital market interests in technology directions and enterprise profiles, as well as overseas market access and marketing strategies [6].

Core Viewpoint - The article emphasizes the importance of a comprehensive understanding of the medical and health ecosystem, highlighting the need for entrepreneurs to develop strategic thinking and innovative capabilities to navigate the complexities of the industry [4][11]. Group 1: Program Overview - The program aims to cultivate leadership talents in the medical and health sector by providing a robust academic support system, innovative platforms, and clinical transformation resources [6][9]. - It features a unique value engine methodology that focuses on collaborative efforts between academia and industry to enhance strategic vision and innovation capabilities [7][8]. Group 2: Course Benefits - The curriculum addresses trends, challenges, and innovations in the medical industry, helping participants understand the development trajectory and future direction of the sector [11]. - It explores how to create a strategic execution path tailored to the specific circumstances of enterprises, enabling them to identify opportunities and mitigate risks in complex environments [12][13]. Group 3: Curriculum Modules - The program includes modules on entrepreneurial thinking in uncertain times, macroeconomic growth logic, and strategic diagnosis and execution [16]. - It covers topics such as value discovery, business model design, and investment and merger decision-making in the healthcare sector [17]. Group 4: Alumni and Networking Opportunities - The program facilitates connections between scientists and entrepreneurs through annual conferences and numerous networking events, enhancing collaboration and resource sharing [20][21]. - It offers international study opportunities at prestigious institutions, fostering a global perspective on healthcare innovation [22][23].